Alice T. Shaw, MD, PhD
The global phase III ALEX trial presented some of the most compelling data the field of ALK-
positive non–small cell lung cancer (NSCLC) has ever seen, enabling a second-generation TKI to be pursued in the frontline setting, said Alice T. Shaw, MD, PhD. These data also opened the door for a more active investigation of sequencing and combination strategies that are contingent upon anticipated resistance mechanisms.
... to read the full story